Indiana University Foundation, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1820-01-20
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.indiana.edu
ADHD Medication Benefits Diminish as Prescription Rates Rise, Swedish Study Reveals
A Swedish population study of 247,420 individuals found that ADHD medications consistently reduced risks of self-harm, unintentional injury, traffic crashes, and crime across all age groups and sexes.
ERA 2025 to Feature Pivotal Nephrology Trials Including CONFIDENCE, ACHIEVE, and VISIONARY Studies
The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.
City of Hope Launches Clinical Trial Testing Osteoporosis Drug for Type 1 Diabetes Treatment
City of Hope has initiated a phase 1/2 clinical trial investigating whether denosumab, an FDA-approved osteoporosis medication, can protect and regenerate insulin-producing beta cells in early-stage type 1 diabetes patients.
Novel Immunotherapy Combinations Show Promise in Advanced Thymic Cancers
Recent clinical trials demonstrate promising results for pembrolizumab plus lenvatinib combination in advanced B3-thymoma and thymic carcinoma, achieving an 88.4% progression-free survival rate at 5 months.
Syrenity Mental Health App Shows Promise in Reducing Depression Symptoms in Indiana University Study
A clinical trial of 135 participants at Indiana University demonstrated that Syrenity app users showed positive trends in reducing depression symptoms compared to non-users over a six-week period.
Adverse Events Linked to Better Survival Outcomes in Enfortumab Vedotin Treatment for Urothelial Cancer
New research reveals patients experiencing neuropathy, skin rash, or hyperglycemia while taking Enfortumab Vedotin showed significantly improved progression-free survival in metastatic urothelial carcinoma treatment.
Artemisinin Resistance Emerges in African Children with Severe Malaria
A new study reveals that malaria parasites in African children are showing resistance to artemisinin, a key drug used to treat the disease.
Real-World Data Show Resmetirom Mirrors Clinical Trial Success in MASH Patients
Real-world data from 72 MASH patients prescribed resmetirom show clinical characteristics and noninvasive test results consistent with phase 3 trial data.